LEPU BIO-B(02157): AstraZeneca has paid a milestone payment of $45 million.

LEPU BIO-B (02157) announced that in February 2023, KYM Biosciences Inc. and AstraZeneca have entered into a global exclusive license agreement to develop and commercialize CMG901 (sonesitatug vedotin, also known as AZD0901, a candidate drug jointly developed by KYM and Connoa). As of the date of this announcement, AstraZeneca has announced the initiation of a multicenter, randomized, controlled, Phase III clinical study (CLARITY-Gastric 02) for sonesitatug vedotin (AZD0901) in combination with capecitabine with or without rilvegostomig as first-line treatment in patients with Claudin 18.2 positive, HER2 negative advanced/metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, and has completed dosing of the first subject. In accordance with the terms and conditions of the license agreement, the completion of dosing of the first subject in the above clinical trial has triggered a related milestone payment, with a total amount of 45 million US dollars. AstraZeneca has paid this milestone payment. KYM is a joint venture established by the company and Connoa, with the company and Connoa holding 30% and 70% respectively. It is primarily engaged in the development and commercialization of CMG901.